Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb;20(2):64.
doi: 10.1038/s41571-022-00725-y.

Engaging results with glofitamab in DLBCL

David Killock  1
Affiliations
Comment

Engaging results with glofitamab in DLBCL

David Killock. Nat Rev Clin Oncol. 2023 Feb.
No abstract available

PubMed Disclaimer

Comment on

  • Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M. Dickinson MJ, et al. N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11. N Engl J Med. 2022. PMID: 36507690 Clinical Trial.

References

Original article
    1. Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220–2231 (2022) - DOI

MeSH terms

LinkOut - more resources